Exclusive Summary

• Patents expired decades ago and the drug is included in the WHO Essential Medicines List, guaranteeing zero IP risks alongside broad clinical recognition globally.
• Covering >50 million epilepsy patients and tens of millions with essential tremor, the availability of both 50 mg and 250 mg strengths perfectly addresses initial titration and long-term maintenance therapies.
• Positioned as an evidence-based first-line treatment for essential tremor, its highly cost-effective and reliable Chinese supply chain can fill regional shortage gaps while securing lucrative margins for distributors.